Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionNatixis Advisors, L.p.
Latest Disclosed Ownership554,024 shares
Latest Disclosed Value $ 247,394
Natixis Advisors, L.p. reports 4.96% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Natixis Advisors, L.p. filed a 13F-HR form disclosing ownership of 554,024 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $247,393,877 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 527,864 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 4.96% during the quarter. The current value of the position is $237,310,640 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 554,024 26,160 4.96 247 3.35 0.3441
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 527,864 -9,330 -1.74 239 13.81 0.3392
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 537,194 -3,336 -0.62 210 -12.50 0.3070
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 540,530 -60,657 -10.09 241 -17.53 0.3818
2025-05-08 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 601,187 43,543 7.81 291 29.91 0.5387
2025-02-10 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 557,644 95,758 20.73 225 4.67 0.4196
2024-11-06 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 461,886 25,301 5.80 215 4.90 0.4189
2024-08-01 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 436,585 104,522 31.48 205 47.83 0.4449
2024-04-25 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 332,063 12,587 3.94 139 6.98 0.3191
2024-02-06 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 319,476 266 0.08 130 16.22 0.3422
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 319,210 -153,998 -32.54 111 -33.13 0.3395
2023-08-15 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 473,208 10,220 2.21 167 14.48 0.5142
2023-05-11 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 462,988 -4,344 -0.93 146 8.21 0.5020
2023-01-27 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 467,332 -41,088 -8.08 135 -99.91 0.5102
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 508,420 -95,775 -15.85 147,208 -13.54 0.6227
2022-08-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 604,195 -66,323 -9.89 170,255 -2.70 0.7487
2022-05-12 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 670,518 2,716 0.41 174,984 19.32 0.6673
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 667,802 51,094 8.28 146,650 31.10 0.5600
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS INDEX FDS VALUE ETF 92532F100 616,708 407,937 195.40 111,865 165.74 0.4600
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 208,771 37,665 22.01 42,095 14.49 0.1965
2021-05-05 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 171,106 30,638 21.81 36,769 10.76 0.1919
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 140,468 -69,574 -33.12 33,198 -41.92 0.1912
2020-11-12 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 210,042 13,085 6.64 57,157 -0.04 0.3597
2020-08-11 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 196,957 40,730 26.07 57,179 53.81 0.3795
2020-04-27 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 156,227 16,901 12.13 37,174 21.86 0.3029
2020-02-10 2019-12-31 13F VERTEX PHARMS COM 92532F100 139,326 1,060 0.77 30,505 30.22 0.2152
2019-11-12 2019-09-30 13F VERTEX PHARMS COM 92532F100 138,266 8,660 6.68 23,425 -1.44 0.1859
2019-08-12 2019-06-30 13F VERTEX PHARMS CL A 92532F100 129,606 8,585 7.09 23,767 6.76 0.1941
2019-05-15 2019-03-31 13F/A-1 VERTEX PHARMS COM 92532F100 121,021 -8,150 -6.31 22,262 4.01 0.1949
2019-05-15 2019-03-31 13F VERTEX PHARMS COM 92532F100 121,021 -8,150 22,262
2019-02-13 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 129,171 2,881 2.28 21,404 -12.07 0.2113
2019-02-13 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 129,171 2,881 21,404
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 126,290 10,203 8.79 24,341 23.37 0.2143
2018-08-14 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 116,087 36,853 46.51 19,730 52.78 0.1885
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 116,087 19,730
2018-05-10 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 79,234 -21 -0.03 12,914 8.73 0.1275
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 79,255 -2,882 -3.51 11,877 -4.89 0.1210
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 82,137 -3,388 -3.96 12,488 13.30 0.1319
2017-07-27 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 85,525 -8,551 -9.09 11,022 7.14 0.1193
2017-05-12 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 94,076 931 1.00 10,287 49.91 0.1140
2017-02-07 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 93,145 23,247 33.26 6,862 12.57 0.0825
2016-11-04 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 69,898 6,663 10.54 6,096 12.08 0.0790
2016-08-01 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 63,235 -1,620 -2.50 5,439 5.51 0.0752
2016-05-06 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 64,855 14,372 28.47 5,155 -18.84 0.0771
2016-02-12 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 50,483 1,814 3.73 6,352 25.34 0.1041
2015-11-12 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 48,669 4,234 9.53 5,068 -7.64 0.0879
2015-08-14 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 44,435 503 1.14 5,487 5.87 0.0932
2015-05-15 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,932 820 1.90 5,183 1.19 0.0910
2015-02-05 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,112 -837 -1.90 5,122 3.77 0.0959
2014-11-03 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 43,949 4,188 10.53 4,936 31.10 0.0990
2014-08-13 2014-06-30 13F VERTEX COM 92532F100 39,761 1,543 4.04 3,765 39.29 0.0539
2014-05-13 2014-03-31 13F VERTEX COM 92532F100 38,218 3,517 10.14 2,703 4.85 0.0416
2014-02-12 2013-12-31 13F VERTEX COM 92532F100 34,701 -937 -2.63 2,578 -4.59 0.0422
2013-10-30 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 35,638 -3,525 -9.00 2,702 -13.84 0.0498
2013-07-19 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 39,163 39,163 3,136 0.0625
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.